Parkin功能丧失增强细胞自噬

Parkin(PARK2)基因的突变与家族性帕金森综合症的发生密切相关,其蛋白Parkin是细胞内的E3泛素连接酶。当线粒体受到损伤时,Parkin会募集到线粒体上,介导线粒体自噬,在生理条件下,Parkin及Parkin突变体是否会引起细胞自噬还不清楚。本文研究了病理性Parkin突变体对细胞自噬的影响。通过构建一系列Parkin功能缺失的突变体,并转染到HeLa以及ATG5-/-MEF细胞中,利用免疫荧光技术和Western-blot分析这些突变体对细胞自噬的影响。结果表明,Parkin突变体的表达促进细胞自噬的标志分子LC3由LC3-Ⅰ型变为LC3-Ⅱ型。突变体R275W在细胞内形成蛋白聚集体,并与LC3共定位。当细胞自噬的关键基因ATG5被敲除后,Parkin突变体引起的细胞自噬受到显著抑制。我们的初步结果提示Parkin突变体通过Atg5影响细胞自噬,并可能与帕金森症的发生有一定的相关性。     

帕金森病相关蛋白Parkin 与PINK1的相互作用研究

帕金森病(Parkinson's disease,PD)是常见的神经系统变性疾病．分子遗传学研究发现,突变的Parkin蛋白及PINK1蛋白均参与了帕金森病的致病过程,但二者之间是否存在相互作用以及是否能够相互调节仍不十分清楚．为明确生理状态下Parkin蛋白与PINK1蛋白之间的相互作用,首先运用蛋白体外结合实验(GST pull-down)技术及免疫共沉淀技术证实了Parkin与PINK1在体外及体内均可相互结合．进一步构建PINK1的不同截短型,运用GST pull-down技术验证了PINK1与Parkin相互结合的区段为PINK1的蛋白激酶结构域．免疫细胞化学实验也证实Parkin与PINK1蛋白在细胞中存在共定位．进一步运用免疫共沉淀技术证实Parkin可减少PINK1通过泛素蛋白酶体系统(ubiquitin proteasome system,UPS)的降解,从而稳定PINK1．PINK1可增加Parkin通过UPS的降解,从而减少Parkin的水平,降低其稳定性．这些结果提示,帕金森病相关蛋白Parkin与PINK1能够直接结合,二者通过泛素蛋白酶体降解系统相互调节,可能协同作用参与了帕金森病的致病过程．     

Parkin基因过表达质粒和细胞模型的构建

目的:构建Parkin基因过表达质粒并转染SH-SY5Y细胞,为进一步研究帕金森病的发病机制及中药的作用环节奠定基础。方法:首先构建Parkin基因过表达质粒,采用脂质体转导技术,将Parkin过表达质粒应用Lipo3000转染SH-SY5Y细胞。荧光显微镜观察细胞绿色荧光蛋白的表达;RT-PCR检测其Parkin mRNA的表达;Western Blot技术检测其Parkin蛋白的表达。结果:转染组可观测到较多的绿色荧光蛋白表达;Parkin过表达细胞Parkin mRNA和蛋白的表达均显著提高(P0.01)。结论:通过脂质体转导技术,应用Lipo3000可将Parkin过表达质粒成功转染入SH-SY5Y细胞,转染的基因和蛋白表达均较高,提示此法可成功构建Parkin基因过表达的细胞模型。     

Parkin， Parkin 底物和帕金森病

Parkin 是隐性遗传性少年型帕金森病的致病基因 . 现认为 Parkin 行使泛素蛋白连接酶功能,参与蛋白质的泛素化过程 . 它的功能缺陷致使其底物蛋白质毒性积聚,从而介导多巴胺能神经元选择性死亡 . 越来越多的研究显示 Parkin 还具有神经保护作用,能对抗多种神经毒性刺激,并且可能参与路易体的形成过程,因此认为它在散发性帕金森病的致病过程中也可能起重要作用 .     

Parkin介导的线粒体自噬及细胞器互作机制

线粒体是细胞生理代谢活动发生的重要场所. 线粒体生发降解平衡是维持能量代谢稳定的重要保障. Parkin作为E3泛素连接酶，通过PINK1/Parkin、LC3等多种信号参与调控线粒体自噬过程. 此外，Parkin还能够影响线粒体相关内质网膜、调控细胞器间钙流，在线粒体-内质网对话过程中调控溶酶体途径介导的线粒体自噬. 脂肪组织是研究线粒体调节机制的理想模型：寒冷刺激诱导富含线粒体的米色脂肪生成；移除刺激后，组织中线粒体消失恢复为白色脂肪，但线粒体稳定性的调控机理目前仍有很多未知. 本文综述Parkin介导线粒体自噬途径的最新研究进展，及其参与线粒体、内质网、溶酶体等不同细胞器间相互作用的调控机制.     

Parkin与α-酮戊二酸载体蛋白(OGCP)的相互作用研究

Parkin基因是帕金森病的致病基因之一,Parkin蛋白作为泛素-蛋白酶体通路(ubiquitin-proteasome pathway,UPP)的一种E3酶,介导了多种底物的泛素化过程,而后者与帕金森病的发病机制有着密切的联系．α-酮戊二酸载体蛋白(2-oxoglutarate carrier protein,OGCP) 是一种线粒体内膜蛋白．采用激光共聚焦技术和免疫共沉淀技术证实,在HEK293细胞中Parkin蛋白与OGCP共定位,且二者之间存在相互作用关系;通过体内、外泛素化实验发现Parkin蛋白能介导OGCP的泛素化．提示OGCP可能是Parkin蛋白的泛素化底物蛋白,且Parkin蛋白能促进OGCP的泛素化．     

稳定表达GFP-Parkin融合蛋白的SH-SY5Y细胞系的建立和功能初探

目的:建立稳定表达GFP-Parkin的SH-SY5Y细胞系,并检测Parkin对MPP~+引起的SH-SY5Y细胞损伤的保护作用。方法:将Parkin编码序列克隆到载体pEGFP-C1中,构建重组质粒pEGFP-Parkin,转染SH-SY5Y细胞,通过G418筛选,建立稳定表达GFP-Parkin的SH-SY5Y细胞系;荧光显微镜和Western印迹鉴定Parkin表达,MTT法检测Parkin对MPP~+致细胞损伤的保护作用。结果:酶切鉴定及测序结果表明重组质粒pEGFP-Parkin构建正确;荧光显微镜下可见细胞内有GFP-Parkin的融合表达,Western印迹检测发现相对分子质量79×103的蛋白条带;MTT结果显示Parkin能够减弱MPP~+对SH-SY5Y细胞的损伤,与对照组相比,存活率高约15%,差异显著(P0.05)。结论:构建了稳定表达GFP-Parkin的SH-SY5Y细胞系,为进一步研究Parkin的细胞保护作用和其他功能机制奠定了基础。     

急性肝损伤时肝脏内Pink1/Parkin的表达变化及意义

目的:观察C57小鼠急性肝损伤(Acute liver injury, ALI)中线粒体自噬相关蛋白Pink1/Parkin表达的变化及意义。方法:领取28只小鼠,随机分为对照组、ALI 1 d组、ALI 4 d组、ALI 7 d组。分别检测血清谷氨酸转氨酶(ALT)、天冬氨酸转氨酶(AST)的变化;肝组织病理变化用HE染色观察;Real Time quality PCR检测Pink1/Parkin在m RNA水平的表达变化;进一步利用Western Blot方法分别检测肝组织中Pink1/Parkin蛋白水平的表达变化。结果:ALI组1 d、4 d、7 d组与对照组相比,ALT、AST表达显著升高,具有统计学意义(P0.05);肝组织病理学检查ALI组1 d和4 d组中,释放出大量的炎性细胞,肝细胞出现大面积坏死,7 d组肝细胞坏死与1 d和4 d比较明显缓解;m RNA水平检测Pink1/Parkin在ALI 1 d(4.79/1.82倍)、4 d(1.74/4.17倍)和7 d(2.91/1.25倍)与对照组相比表达水平明显升高(P0.05);Pink1/Parkin在蛋白水平检测时ALI 1 d(2.03/1.82倍)、4 d(1.78/4.17倍)和7 d(1.25/1.25倍)时肝组织内表达也显著增加,差异具有统计学意义(P0.05)。结论:急性肝损伤状态下Pink1/Parkin在m RNA和蛋白水平表达升高,且其表达量随着肝脏的损伤缓解而表达水平降低,提示Pink1/Parkin可能对于治疗急性肝损伤具有重要意义。     

帕金森病相关蛋白PINK1和Parkin通过降解Miro影响线粒体运动

帕金森病是一种常见的神经退行性疾病,发病机制尚不清楚,线粒体功能障碍是可能的原因之一。帕金森病相关蛋白PINK1和Parkin均被证明影响线粒体功能和形态,并参与线粒体质量监控。2011年11月《细胞》杂志 （Cell）147期 发表了题为《PINK1和Parkin导致Miro磷酸化降解和线粒体运动阻滞》的文章,发现PINK1 / Parkin 通路可以作用于定位在线粒体外膜的线粒体移动相关蛋白Miro,PINK1直接磷酸化Miro,Parkin参与Miro降解,使受损线粒体脱离微管,从而阻滞线粒体运动。作者猜测这一过程能够隔离受损线粒体,避免了受损线粒体在细胞中的扩散。该研究深入探讨了PINK1和Parkin相互作用机制,揭示了线粒体质量控制系统如何直接调控线粒体运输,提出了受损线粒体的不正常运输可能是PD的致病原因。     

Pink1/Parkin信号通路调控线粒体自噬的研究进展

线粒体自噬是指为了维持细胞内环境稳定而通过选择性自噬来降解功能失调或过剩的线粒体。在众多线粒体自噬相关通路研究中,对Pink1/Parkin信号通路的探索较为详细。在哺乳动物细胞中,Ser/Thr蛋白激酶Pink1和E3泛素连接酶Parkin协同作用,感知线粒体功能状态并对受损的线粒体进行标记,以促进其通过自噬途径进行降解。同时,泛素化和去泛素化在调节Parkin和线粒体自噬活性中起着重要的作用。本文就Pink1/Parkin信号通路以及去泛素化酶在线粒体自噬中的作用进行综述。     

PINK1 as a molecular checkpoint in the maintenance of mitochondrial function and integrity

Parkinson's disease (PD), the most prevalent neurodegenerative movement disorder, is characterized by an age-dependent selective loss of dopaminergic (DA) neurons. Although most PD cases are sporadic, more than 20 responsible genes in familial cases were identified recently. Genetic studies using Drosophila models demonstrate that PINK1, a mitochondrial kinase encoded by a PD-linked gene PINK1, is critical for maintaining mitochondrial function and integrity. This suggests that mitochondrial dysfunction is the main cause of PD pathogenesis. Further genetic and cell biological studies revealed that PINK1 recruits Parkin, an E3 ubiquitin ligase encoded by another PD-linked gene parkin, to mitochondria and regulates the mitochondrial remodeling process via the Parkin-mediated ubiquitination of various mitochondrial proteins. PINK1 also directly phosphorylates the mitochondrial proteins Miro and TRAP1, subsequently inhibiting mitochondrial transport and mitochondrial oxidative damage, respectively. Moreover, recent Drosophila genetic analyses demonstrate that the neuroprotective molecules Sir2 and FOXO specifically complement mitochondrial dysfunction and DA neuron loss in PINK1 null mutants, suggesting that Sir2 and FOXO protect mitochondria and DA neurons downstream of PINK1. Collectively, these recent results suggest that PINK1 plays multiple roles in mitochondrial quality control by regulating its mitochondrial, cytosolic, and nuclear targets.     

Parkin、PINK1、DJ-1和线粒体功能障碍与帕金森病

帕金森病(Parkinson’s disese,PD)是一种常见的神经退行性疾病,但到目前为止发病机制尚不明确,环境和遗传等因素与其发病有密切关系。研究表明,蛋白质异常积聚(泛素/蛋白酶体途径)和线粒体氧化损伤(线粒体途径),可能是导致PD患者发病的关键分子机制。Parkin、PINK1和DJ-1等基因突变与常染色体隐性的家族性PD有关,这些相关基因编码的蛋白对于维持线粒体形态和功能起着重要的作用。本文将主要从Parkin、PINK1、DJ-1和线粒体功能障碍与帕金森病的关系进行综述。     

The ubiquitin signal and autophagy: an orchestrated dance leading to mitochondrial degradation

The quality of mitochondria, essential organelles that produce ATP and regulate numerous metabolic pathways, must be strictly monitored to maintain cell homeostasis. The loss of mitochondrial quality control systems is acknowledged as a determinant for many types of neurodegenerative diseases including Parkinson's disease (PD). The two gene products mutated in the autosomal recessive forms of familial early‐onset PD, Parkin and PINK1, have been identified as essential proteins in the clearance of damaged mitochondria via an autophagic pathway termed mitophagy. Recently, significant progress has been made in understanding how the mitochondrial serine/threonine kinase PINK1 and the E3 ligase Parkin work together through a novel stepwise cascade to identify and eliminate damaged mitochondria, a process that relies on the orchestrated crosstalk between ubiquitin/phosphorylation signaling and autophagy. In this review, we highlight our current understanding of the detailed molecular mechanisms governing Parkin‐/PINK1‐mediated mitophagy and the evidences connecting Parkin/PINK1 function and mitochondrial clearance in neurons.     

Parkin mitochondrial translocation is achieved through a novel catalytic activity coupled mechanism

Pink1, a mitochondrial kinase, and Parkin, an E3 ubiquitin ligase, function in mitochondrial maintenance. Pink1 accumulates on depolarized mitochondria, where it recruits Parkin to mainly induce K63-linked chain ubiquitination of outer membrane proteins and eventually mitophagy. Parkin belongs to the RBR E3 ligase family. Recently, it has been proposed that the RBR domain transfers ubiquitin to targets via a cysteine∼ubiquitin enzyme intermediate, in a manner similar to HECT domain E3 ligases. However, direct evidence for a ubiquitin transfer mechanism and its importance for Parkin''s in vivo function is still missing. Here, we report that Parkin E3 activity relies on cysteine-mediated ubiquitin transfer during mitophagy. Mutating the putative catalytic cysteine to serine (Parkin C431S) traps ubiquitin, and surprisingly, also abrogates Parkin mitochondrial translocation, indicating that E3 activity is essential for Parkin translocation. We found that Parkin can bind to K63-linked ubiquitin chains, and that targeting K63-mimicking ubiquitin chains to mitochondria restores Parkin C431S localization. We propose that Parkin translocation is achieved through a novel catalytic activity coupled mechanism.     

Proteomic analysis of increased Parkin expression and its interactants provides evidence for a role in modulation of mitochondrial function

Parkin is an ubiquitin‐protein ligase (E3), mutations of which cause juvenile onset – autosomal recessive Parkinson's disease, and result in reduced enzymic activity. In contrast, increased levels are protective against mitochondrial dysfunction and neurodegeneration, the mechanism of which is largely unknown. In this study, 2‐DE and MS proteomic techniques were utilised to investigate the effects of increased Parkin levels on protein expression in whole cell lysates using in an inducible Parkin expression system in HEK293 cells, and also to isolate potential interactants of Parkin using tandem affinity purification and MS. Nine proteins were significantly differentially expressed (±2‐fold change; p<0.05) using 2‐DE analysis. MS revealed the identity of these proteins to be ACAT2, HNRNPK, HSPD1, PGK1, PRDX6, VCL, VIM, TPI1, and IMPDH2. The first seven of these were reduced in expression. Western blot analysis confirmed the reduction in one of these proteins (HNRNPK), and that its levels were dependent on 26S proteasomal activity. Tandem affinity purification/MS revealed 14 potential interactants of Parkin; CKB, DBT, HSPD1, HSPA9, LRPPRC, NDUFS2, PRDX6, SLC25A5, TPI1, UCHL1, UQCRC1, VCL, YWHAZ, YWHAE. Nine of these are directly involved in mitochondrial energy metabolism and glycolysis; four were also identified in the 2‐DE study (HSP60, PRDX6, TPI1, and VCL). This study provides further evidence for a role for Parkin in regulating mitochondrial activity within cells.     

Parkin promotes degradation of the mitochondrial pro-apoptotic ARTS protein

Parkinson's disease (PD) is associated with excessive cell death causing selective loss of dopaminergic neurons. Dysfunction of the Ubiquitin Proteasome System (UPS) is associated with the pathophysiology of PD. Mutations in Parkin which impair its E3-ligase activity play a major role in the pathogenesis of inherited PD. ARTS (Sept4_i2) is a mitochondrial protein, which initiates caspase activation upstream of cytochrome c release in the mitochondrial apoptotic pathway. Here we show that Parkin serves as an E3-ubiquitin ligase to restrict the levels of ARTS through UPS-mediated degradation. Though Parkin binds equally to ARTS and Sept4_i1 (H5/PNUTL2), the non-apoptotic splice variant of Sept4, Parkin ubiquitinates and degrades only ARTS. Thus, the effect of Parkin on ARTS is specific and probably related to its pro-apoptotic function. High levels of ARTS are sufficient to promote apoptosis in cultured neuronal cells, and rat brains treated with 6-OHDA reveal high levels of ARTS. However, over-expression of Parkin can protect cells from ARTS-induced apoptosis. Furthermore, Parkin loss-of-function experiments reveal that reduction of Parkin causes increased levels of ARTS and apoptosis. We propose that in brain cells in which the E3-ligase activity of Parkin is compromised, ARTS levels increase and facilitate apoptosis. Thus, ARTS is a novel substrate of Parkin. These observations link Parkin directly to a pro-apoptotic protein and reveal a novel connection between Parkin, apoptosis, and PD.     

Loss of neuronal Miro1 disrupts mitophagy and induces hyperactivation of the integrated stress response

Clearance of mitochondria following damage is critical for neuronal homeostasis. Here, we investigate the role of Miro proteins in mitochondrial turnover by the PINK1/Parkin mitochondrial quality control system in vitro and in vivo. We find that upon mitochondrial damage, Miro is promiscuously ubiquitinated on multiple lysine residues. Genetic deletion of Miro or block of Miro1 ubiquitination and subsequent degradation lead to delayed translocation of the E3 ubiquitin ligase Parkin onto damaged mitochondria and reduced mitochondrial clearance in both fibroblasts and cultured neurons. Disrupted mitophagy in vivo, upon post‐natal knockout of Miro1 in hippocampus and cortex, leads to a dramatic increase in mitofusin levels, the appearance of enlarged and hyperfused mitochondria and hyperactivation of the integrated stress response (ISR). Altogether, our results provide new insights into the central role of Miro1 in the regulation of mitochondrial homeostasis and further implicate Miro1 dysfunction in the pathogenesis of human neurodegenerative disease.     

Mitochondrial processing peptidase regulates PINK1 processing, import and Parkin recruitment

Mutations in phosphatase and tensin homologue-induced kinase 1 (PINK1) cause recessively inherited Parkinson's disease (PD), a neurodegenerative disorder linked to mitochondrial dysfunction. In healthy mitochondria, PINK1 is rapidly degraded in a process involving both mitochondrial proteases and the proteasome. However, when mitochondrial import is compromised by depolarization, PINK1 accumulates on the mitochondrial surface where it recruits the PD-linked E3 ubiquitin ligase Parkin from the cytosol, which in turn mediates the autophagic destruction of the dysfunctional organelles. Using an unbiased RNA-mediated interference (RNAi)-based screen, we identified four mitochondrial proteases, mitochondrial processing peptidase (MPP), presenilin-associated rhomboid-like protease (PARL), m-AAA and ClpXP, involved in PINK1 degradation. We find that PINK1 turnover is particularly sensitive to even modest reductions in MPP levels. Moreover, PINK1 cleavage by MPP is coupled to import such that reducing MPP activity induces PINK1 accumulation at the mitochondrial surface, leading to Parkin recruitment and mitophagy. These results highlight a new role for MPP in PINK1 import and mitochondrial quality control via the PINK1–Parkin pathway.     

Interaction between RING1 (R1) and the Ubiquitin-like (UBL) Domains Is Critical for the Regulation of Parkin Activity

Parkin is an E3 ligase that contains a ubiquitin-like (UBL) domain in the N terminus and an R1-in-between-ring-RING2 motif in the C terminus. We showed that the UBL domain specifically interacts with the R1 domain and negatively regulates Parkin E3 ligase activity, Parkin-dependent mitophagy, and Parkin translocation to the mitochondria. The binding between the UBL domain and the R1 domain was suppressed by carbonyl cyanide m-chlorophenyl hydrazone treatment or by expression of PTEN-induced putative kinase 1 (PINK1), an upstream kinase that phosphorylates Parkin at the Ser-65 residue of the UBL domain. Moreover, we demonstrated that phosphorylation of the UBL domain at Ser-65 prevents its binding to the R1 domain and promotes Parkin activities. We further showed that mitochondrial translocation of Parkin, which depends on phosphorylation at Ser-65, and interaction between the R1 domain and a mitochondrial outer membrane protein, VDAC1, are suppressed by binding of the UBL domain to the R1 domain. Interestingly, Parkin with missense mutations associated with Parkinson disease (PD) in the UBL domain, such as K27N, R33Q, and A46P, did not translocate to the mitochondria and induce E3 ligase activity by m-chlorophenyl hydrazone treatment, which correlated with the interaction between the R1 domain and the UBL domain with those PD mutations. These findings provide a molecular mechanism of how Parkin recruitment to the mitochondria and Parkin activation as an E3 ubiquitin ligase are regulated by PINK1 and explain the previously unknown mechanism of how Parkin mutations in the UBL domain cause PD pathogenesis.     

Binding to serine 65‐phosphorylated ubiquitin primes Parkin for optimal PINK1‐dependent phosphorylation and activation

Mutations in the mitochondrial protein kinase PINK1 are associated with autosomal recessive Parkinson disease (PD). We and other groups have reported that PINK1 activates Parkin E3 ligase activity both directly via phosphorylation of Parkin serine 65 (Ser⁶⁵)—which lies within its ubiquitin‐like domain (Ubl)—and indirectly through phosphorylation of ubiquitin at Ser⁶⁵. How Ser⁶⁵‐phosphorylated ubiquitin (ubiquitin^{Phospho‐Ser65}) contributes to Parkin activation is currently unknown. Here, we demonstrate that ubiquitin^{Phospho‐Ser65} binding to Parkin dramatically increases the rate and stoichiometry of Parkin phosphorylation at Ser⁶⁵ by PINK1 in vitro. Analysis of the Parkin structure, corroborated by site‐directed mutagenesis, shows that the conserved His302 and Lys151 residues play a critical role in binding of ubiquitin^{Phospho‐Ser65}, thereby promoting Parkin Ser⁶⁵ phosphorylation and activation of its E3 ligase activity in vitro. Mutation of His302 markedly inhibits Parkin Ser⁶⁵ phosphorylation at the mitochondria, which is associated with a marked reduction in its E3 ligase activity following mitochondrial depolarisation. We show that the binding of ubiquitin^{Phospho‐Ser65} to Parkin disrupts the interaction between the Ubl domain and C‐terminal region, thereby increasing the accessibility of Parkin Ser⁶⁵. Finally, purified Parkin maximally phosphorylated at Ser⁶⁵ in vitro cannot be further activated by the addition of ubiquitin^{Phospho‐Ser65}. Our results thus suggest that a major role of ubiquitin^{Phospho‐Ser65} is to promote PINK1‐mediated phosphorylation of Parkin at Ser⁶⁵, leading to maximal activation of Parkin E3 ligase activity. His302 and Lys151 are likely to line a phospho‐Ser⁶⁵‐binding pocket on the surface of Parkin that is critical for the ubiquitin^{Phospho‐Ser65} interaction. This study provides new mechanistic insights into Parkin activation by ubiquitin^{Phospho‐Ser65}, which could aid in the development of Parkin activators that mimic the effect of ubiquitin^{Phospho‐Ser65}.